View Older Stories View More Recent Stories
-
Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC
-
Deerfield Management Announces 2023 XSeed Award Winners
-
Deerfield Management Announces $25M Grant from New York State and Empire State Development to Build a Lab of the Future at Healthcare Innovation Campus, Cure®
-
Valneva SE (VALN) Reports FY22 Revenue of EUR 361.3M, Loss of EUR 143.3M, Guides FY23 Revenue of EUR 220M-260M
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
-
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
-
InVitae (NVTA) and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
-
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
-
Axon Therapies Cohort Study Extends Benefit to 6 months with Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
-
CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
-
CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
-
Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates
-
Adela to present data demonstrating detection of multiple cancer types at the American Association for Cancer Research Annual Meeting 2023
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
-
Form SC 13D/A CareMax, Inc. Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
-
The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
-
Cure® to Host "Moonshots and More," A Fireside Chat with President and CEO of Dana-Farber Cancer Institute, Laurie H. Glimcher, M.D.
-
MMI Named One of Fast Company’s 2023 “World’s Most Innovative Companies”
-
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance
-
Cure® Launches New Event Series, CureX, on Rare Disease Day with Keynote Speaker and Entrepreneurial Trailblazer, Jamie Heywood
-
IRONMATT RECEIVES $75,000 GRANT FROM DEERFIELD FOUNDATION
-
Form 13F-HR DEERFIELD MANAGEMENT For: Dec 31
-
Fusion Pharmaceuticals (FUSN) Announces 17.6M Share Offering at $3.40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T
-
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
-
Caris Life Sciences Raises $400 Million in Senior Secured Debt
-
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection
-
Alphatec Holdings (ATEC) Prelim. Q4 revenue tops consensus
-
ATEC Announces Select Preliminary Financial 2022 Results, 2023 Guidance and Closing of Flexible, Non-Dilutive Debt Facility
-
The Retinal Degeneration Fund invests in a $78M Series B for Perceive Biotherapeutics
-
Cold Spring Harbor Laboratory and Deerfield Management Launch Harbor Discoveries to Advance New Therapeutics
-
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
-
MMI to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
Insider trading convictions over healthcare leaks are voided by U.S. appeals court
-
Miravo Healthcare™ Enters into Definitive Agreement to be Acquired by Searchlight Pharma Inc.
-
Lumos Pharma, Inc. (LUMO) Announces KOL Review of Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
Endologix Receives FDA Approval of PMA Supplement for AFX2 System
-
Healthcare and Life sciences Convener, Cure®, to Host Fireside Chat with Pulitzer Prize-Winner and New York Times Bestselling Author, Siddhartha Mukherjee
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Deerfield Management Announces Third Annual XSeed Award to Support Underfunded and Underrepresented NYC Life Science Startups
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Form 4 CareMax, Inc. For: Nov 17 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
-
Quartet Launches Behavioral Health Care Clinic for Patients with Moderate to Severe Mental Illness
